Recently Featured

Vedana Debuts with $46M to Progress Migraine Therapies

June 19, 2026
Vedana Therapeutics has successfully secured $46 million in funding to advance its clinical pipeline focused on innovative migraine therapies. This significant financial backing underscores the growing interest in targeting the PACAP pathway, which has yielded mixed results in previous migraine clinical trials. As the pharmaceutical industry continues to explore novel approaches to migraine treatment, Vedana’s…

Jazz zeroes in on next-gen T cell engagers with AbCellera deal

June 19, 2026
The potentially $4 billion collaboration between Jazz Pharmaceuticals and AbCellera marks a significant step in the evolution of T cell engagers, a class of therapeutics that have thus far demonstrated limited efficacy primarily in blood cancers. This partnership aims to leverage AbCellera’s cutting-edge antibody discovery platform to develop next-generation multispecific antibodies, which could enhance the…

Novo Nordisk Launches Czech Manufacturing Plant for Next-Generation Diabetes Drugs and Invests $29M in China Facility

June 18, 2026
Eighteen months after acquiring a facility in the Czech Republic from Novavax, Novo Nordisk has officially commenced the production of active pharmaceutical ingredients for its next-generation diabetes and obesity treatments. This strategic move underscores the company’s commitment to expanding its manufacturing capabilities in Europe, particularly in response to the increasing global demand for innovative diabetes…

Age-Related Inflammation Linked to R-Loop Nucleic Acids, Opens Therapies

June 18, 2026
In a new study published in Nature Aging, researchers from the University of Texas (UT) MD Anderson Cancer Center have uncovered a previously unknown connection between R-loop nucleic acid structures and age-related inflammation, also known as inflammaging. This discovery paves the way for new therapeutic interventions targeting chronic inflammation and its associated health conditions. In…

Ongoing Cases